JP2021020948A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021020948A5 JP2021020948A5 JP2020179494A JP2020179494A JP2021020948A5 JP 2021020948 A5 JP2021020948 A5 JP 2021020948A5 JP 2020179494 A JP2020179494 A JP 2020179494A JP 2020179494 A JP2020179494 A JP 2020179494A JP 2021020948 A5 JP2021020948 A5 JP 2021020948A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 6
- PETFFVPRVBVQKQ-IBGZPJMESA-N CC(C)c1nccc(C)c1N(c(c(C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)c2)nc(-c(c(F)ccc3)c3O)c2F)C1=O Chemical compound CC(C)c1nccc(C)c1N(c(c(C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=N1)c2)nc(-c(c(F)ccc3)c3O)c2F)C1=O PETFFVPRVBVQKQ-IBGZPJMESA-N 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022099389A JP7495444B2 (ja) | 2017-05-22 | 2022-06-21 | Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法 |
| JP2024083128A JP7717224B2 (ja) | 2017-05-22 | 2024-05-22 | Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762509629P | 2017-05-22 | 2017-05-22 | |
| US62/509,629 | 2017-05-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018097648A Division JP6785819B2 (ja) | 2017-05-22 | 2018-05-22 | Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022099389A Division JP7495444B2 (ja) | 2017-05-22 | 2022-06-21 | Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021020948A JP2021020948A (ja) | 2021-02-18 |
| JP2021020948A5 true JP2021020948A5 (enExample) | 2021-11-11 |
| JP7095052B2 JP7095052B2 (ja) | 2022-07-04 |
Family
ID=62620997
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018097648A Active JP6785819B2 (ja) | 2017-05-22 | 2018-05-22 | Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法 |
| JP2020179494A Active JP7095052B2 (ja) | 2017-05-22 | 2020-10-27 | Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法 |
| JP2022099389A Active JP7495444B2 (ja) | 2017-05-22 | 2022-06-21 | Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法 |
| JP2024083128A Active JP7717224B2 (ja) | 2017-05-22 | 2024-05-22 | Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018097648A Active JP6785819B2 (ja) | 2017-05-22 | 2018-05-22 | Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022099389A Active JP7495444B2 (ja) | 2017-05-22 | 2022-06-21 | Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法 |
| JP2024083128A Active JP7717224B2 (ja) | 2017-05-22 | 2024-05-22 | Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法 |
Country Status (39)
Families Citing this family (220)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY196830A (en) * | 2016-12-22 | 2023-05-03 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| AR112797A1 (es) | 2017-09-08 | 2019-12-11 | Amgen Inc | Inhibidores de kras g12c y métodos para utilizarlos |
| CN119569702A (zh) | 2018-04-04 | 2025-03-07 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| WO2019213516A1 (en) * | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| AU2019262599B2 (en) | 2018-05-04 | 2023-10-12 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| ES2986917T3 (es) | 2018-05-10 | 2024-11-13 | Amgen Inc | Inhibidores de KRAS G12C para el tratamiento del cáncer |
| CA3098885A1 (en) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| US20190375749A1 (en) * | 2018-06-11 | 2019-12-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| JP7369719B2 (ja) * | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法 |
| ES2950007T3 (es) | 2018-06-27 | 2023-10-04 | Bristol Myers Squibb Co | Compuestos de naftiridinona útiles como activadores de células T |
| BR112020026681A2 (pt) | 2018-06-27 | 2021-04-06 | Bristol-Myers Squibb Company | Compostos naftiridinona substituídos úteis como ativadores de célula t |
| US12065430B2 (en) | 2018-10-26 | 2024-08-20 | Taiho Pharmaceutical Co., Ltd. | Indazole compound or salt thereof |
| JP7516029B2 (ja) * | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| US11053226B2 (en) | 2018-11-19 | 2021-07-06 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| EP3894396A1 (en) | 2018-12-10 | 2021-10-20 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| KR20210121168A (ko) * | 2019-01-29 | 2021-10-07 | 브라이트제네 바이오-메디컬 테크놀로지 코., 엘티디. | 복소환식 화합물인 벤조피리돈 및 그 사용 |
| CN113382774A (zh) * | 2019-02-12 | 2021-09-10 | 诺华股份有限公司 | 包含tno155和krasg12c抑制剂的药物组合 |
| WO2020178282A1 (en) | 2019-03-05 | 2020-09-10 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| JP7684910B2 (ja) * | 2019-04-22 | 2025-05-28 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 小児対象において神経膠腫を治療するためのｔｇ０２の使用 |
| CN114025772A (zh) * | 2019-04-24 | 2022-02-08 | 纪念斯隆凯特琳癌症中心 | 用于治疗ras突变体癌症的组合物和方法 |
| WO2020221239A1 (zh) * | 2019-04-28 | 2020-11-05 | 劲方医药科技(上海)有限公司 | 氧杂氮杂喹唑啉-7(8h)-酮类化合物，其制法与医药上的用途 |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| CA3225293A1 (en) * | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
| MX2021014096A (es) * | 2019-05-21 | 2022-02-11 | Inventisbio Co Ltd | Compuestos heterociclicos, metodos de preparacion y usos de estos. |
| US12252486B2 (en) | 2019-05-21 | 2025-03-18 | Amgen Inc. | Solid state forms |
| WO2020239077A1 (zh) * | 2019-05-29 | 2020-12-03 | 上海翰森生物医药科技有限公司 | 含氮杂环类衍生物调节剂、其制备方法和应用 |
| CN112552294B (zh) * | 2019-09-10 | 2023-12-19 | 上海翰森生物医药科技有限公司 | 含哌嗪杂环类衍生物抑制剂、其制备方法和应用 |
| CN113396147B (zh) * | 2019-05-31 | 2024-06-18 | 上海翰森生物医药科技有限公司 | 芳香杂环类衍生物调节剂、其制备方法和应用 |
| CA3144548A1 (en) * | 2019-06-24 | 2020-12-30 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of kras g12c |
| WO2020259573A1 (zh) * | 2019-06-25 | 2020-12-30 | 南京明德新药研发有限公司 | 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物 |
| CN110256421A (zh) * | 2019-06-26 | 2019-09-20 | 微境生物医药科技(上海)有限公司 | Kras-g12c抑制剂 |
| CN114040914B (zh) * | 2019-07-01 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 |
| CN112300194B (zh) * | 2019-07-30 | 2022-01-14 | 上海凌达生物医药有限公司 | 一类稠环吡啶酮类化合物、制备方法和用途 |
| EP4011886A4 (en) * | 2019-08-02 | 2023-07-26 | Shanghai Jemincare Pharmaceuticals Co., Ltd. | TETRACYCLIC COMPOUND, METHOD FOR PREPARATION AND USE |
| WO2021023247A1 (en) * | 2019-08-07 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitor |
| CN112390788A (zh) * | 2019-08-13 | 2021-02-23 | 苏州闻天医药科技有限公司 | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 |
| CN112390797A (zh) * | 2019-08-15 | 2021-02-23 | 微境生物医药科技(上海)有限公司 | 新型螺环类K-Ras G12C抑制剂 |
| CN112390796B (zh) * | 2019-08-19 | 2023-06-27 | 贝达药业股份有限公司 | Kras g12c抑制剂及其在医药上的应用 |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| EP4029853A4 (en) | 2019-09-11 | 2023-03-01 | Chiral Quest (suzhou) Co., Ltd. | SYNTHETIC METHOD APPLIED TO A HETEROCYCLIC INTERMEDIATE OF KRAS INHIBITOR DRUGS |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CN116947885A (zh) * | 2019-09-20 | 2023-10-27 | 上海济煜医药科技有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
| CN114761012B (zh) * | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| EP4041399A1 (en) | 2019-10-02 | 2022-08-17 | Tolremo Therapeutics AG | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
| WO2021076655A1 (en) | 2019-10-15 | 2021-04-22 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| EP4048671A1 (en) * | 2019-10-24 | 2022-08-31 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| CN112225734B (zh) * | 2019-10-25 | 2021-12-07 | 南京瑞捷医药科技有限公司 | Kras g12c抑制剂及其用途 |
| PE20221253A1 (es) | 2019-10-28 | 2022-08-16 | Merck Sharp & Dohme | Inhibidores de pequenas moleculas de mutante g12c de kras |
| CA3156777A1 (en) * | 2019-10-30 | 2021-05-06 | Fusheng ZHOU | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof |
| CA3160142A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2021091967A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN115894606A (zh) | 2019-11-04 | 2023-04-04 | 锐新医药公司 | Ras抑制剂 |
| EP4058453A1 (en) * | 2019-11-14 | 2022-09-21 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| US12473281B2 (en) | 2019-11-14 | 2025-11-18 | Amgen Inc. | Synthesis of KRAS G12C inhibitor compound |
| WO2021093758A1 (zh) * | 2019-11-15 | 2021-05-20 | 四川海思科制药有限公司 | 一种嘧啶并环衍生物及其在医药上的应用 |
| KR20220133866A (ko) | 2019-11-27 | 2022-10-05 | 터닝 포인트 테라퓨틱스, 인크. | 디아릴 매크로시클릭 화합물을 수반하는 병용 요법 |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| CN113614080B (zh) * | 2019-11-29 | 2022-06-28 | 苏州信诺维医药科技股份有限公司 | Kras g12c抑制剂化合物及其用途 |
| CN111377918B (zh) * | 2019-11-29 | 2021-03-02 | 苏州信诺维医药科技有限公司 | 一种kras抑制剂化合物 |
| WO2021113595A1 (en) * | 2019-12-06 | 2021-06-10 | Beta Pharma, Inc. | Phosphorus derivatives as kras inhibitors |
| IL293738A (en) * | 2019-12-10 | 2022-08-01 | Univ Texas | Compositions and methods for substituted 7-(piperazin-1-yl)pyrazolo[1,5-a]pyrimidine analogs as inhibitors of kras |
| US20230028414A1 (en) | 2019-12-16 | 2023-01-26 | Amgen Inc. | Dosing regimen of kras g12c inhibitor |
| WO2021120045A1 (en) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| KR20220119088A (ko) | 2019-12-19 | 2022-08-26 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Kras 돌연변이체 단백질 억제제 |
| WO2021120890A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| BR112022012222A2 (pt) | 2019-12-23 | 2022-09-13 | Bristol Myers Squibb Co | Derivados de piperazina substituídos úteis como ativadores de células t |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| WO2021139678A1 (zh) * | 2020-01-07 | 2021-07-15 | 广州百霆医药科技有限公司 | 吡啶并嘧啶类kras g12c突变蛋白抑制剂 |
| TWI770760B (zh) * | 2020-01-08 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 螺環四氫喹唑啉 |
| CN111205286B (zh) * | 2020-01-13 | 2022-12-13 | 中科苏州药物研究院 | 作为kras g12c突变蛋白抑制剂的腈甲基哌嗪类衍生物及其应用 |
| CN114671866A (zh) * | 2020-12-25 | 2022-06-28 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| US11530218B2 (en) | 2020-01-20 | 2022-12-20 | Incyte Corporation | Spiro compounds as inhibitors of KRAS |
| CN115003668A (zh) * | 2020-01-21 | 2022-09-02 | 南京明德新药研发有限公司 | 作为kras抑制剂的大环类化合物 |
| GB202001344D0 (en) | 2020-01-31 | 2020-03-18 | Redx Pharma Plc | Ras Inhibitors |
| CN112159405B (zh) * | 2020-02-04 | 2021-09-14 | 广州必贝特医药技术有限公司 | 吡啶并嘧啶酮类化合物及其应用 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| CN113248521B (zh) * | 2020-02-11 | 2023-07-18 | 上海和誉生物医药科技有限公司 | 一种k-ras g12c抑制剂及其制备方法和应用 |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| JP7462985B2 (ja) * | 2020-02-24 | 2024-04-08 | 上海▲テツ▼▲ギョウ▼生物科技有限公司 | 芳香族化合物および抗腫瘍薬物の調製におけるその使用 |
| CN114901663B (zh) * | 2020-03-02 | 2024-07-02 | 上海喆邺生物科技有限公司 | 一类芳香杂环类化合物及其在药物中的应用 |
| WO2021185233A1 (en) * | 2020-03-17 | 2021-09-23 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
| CN115244931A (zh) | 2020-04-03 | 2022-10-25 | 英特尔公司 | 用于识别视频解码差错的方法和装置 |
| EP4129997A4 (en) * | 2020-04-03 | 2024-01-24 | Medshine Discovery Inc. | OCTAHYDROPYRAZINODIAZANAPHTHYRIDINDIONE COMPOUNDS |
| US20230203055A1 (en) * | 2020-04-28 | 2023-06-29 | Betta Pharmaceuticals Co., Ltd | Fused ring compound and application thereof in medicine |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| JP2023526443A (ja) | 2020-05-18 | 2023-06-21 | ウェルマーカー バイオ カンパニー リミテッド | Ｒｏｎ変異が関与する非小細胞肺がんの予防又は治療用医薬組成物及びその使用方法 |
| CN112574199B (zh) * | 2020-05-20 | 2021-05-18 | 首药控股(北京)股份有限公司 | Kras-G12C抑制剂杂环化合物 |
| EP4153588A1 (en) * | 2020-05-20 | 2023-03-29 | Teva Pharmaceuticals International GmbH | Solid state forms of amg-510 and process for preparation thereof |
| US20230212164A1 (en) | 2020-06-02 | 2023-07-06 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CN114585624A (zh) * | 2020-06-02 | 2022-06-03 | 上海喆邺生物科技有限公司 | 一种手性中间体及其制备方法 |
| WO2021249563A1 (zh) * | 2020-06-12 | 2021-12-16 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| JP2023530351A (ja) | 2020-06-18 | 2023-07-14 | レヴォリューション・メディスンズ，インコーポレイテッド | Ｒａｓ阻害剤への獲得耐性を遅延させる、防止する、及び、治療する方法 |
| JP2023531049A (ja) | 2020-06-24 | 2023-07-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｏｓ１阻害剤及びｋｒａｓ ｇ１２ｃ阻害剤を含む抗がん剤併用療法 |
| KR20230028798A (ko) * | 2020-06-25 | 2023-03-02 | 톨레모 테라퓨틱스 아게 | 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물 |
| CN113929676A (zh) * | 2020-07-14 | 2022-01-14 | 浙江海正药业股份有限公司 | 吡啶并杂环类衍生物及其制备方法和用途 |
| CN113980032B (zh) * | 2020-07-27 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
| JP7584815B2 (ja) * | 2020-08-02 | 2024-11-18 | 上▲海▼▲哲▼▲イェ▼生物科技有限公司 | 抗腫瘍薬物における芳香族化合物及びその用途 |
| WO2022037560A1 (zh) * | 2020-08-21 | 2022-02-24 | 广东东阳光药业有限公司 | 嘧啶酮衍生物及其在药物中的应用 |
| CN116406363B (zh) * | 2020-08-21 | 2025-06-20 | 浙江海正药业股份有限公司 | 四环类衍生物、其制备方法及其医药上的用途 |
| CN116368130A (zh) | 2020-08-28 | 2023-06-30 | 金橘生物科技公司 | 杂环化合物及其用途 |
| US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
| KR20230081726A (ko) | 2020-09-03 | 2023-06-07 | 레볼루션 메디슨즈, 인크. | Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도 |
| KR20230067635A (ko) | 2020-09-15 | 2023-05-16 | 레볼루션 메디슨즈, 인크. | 암의 치료에서 ras 억제제로서 인돌 유도체 |
| KR20230094198A (ko) | 2020-09-23 | 2023-06-27 | 에라스카, 아이엔씨. | 3환식 피리돈 및 피리미돈 |
| US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
| CA3196612A1 (en) | 2020-10-07 | 2022-04-14 | Amgen Inc. | Process for racemizing and isolating atropisomers of 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione |
| EP4232444A4 (en) | 2020-10-20 | 2024-09-11 | Amgen Inc. | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE |
| AU2021370660A1 (en) | 2020-10-27 | 2023-06-08 | Amgen Inc. | Heterocyclic spiro compounds and methods of use |
| WO2022103905A1 (en) * | 2020-11-13 | 2022-05-19 | Genentech, Inc. | Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors |
| EP4247813A1 (en) * | 2020-11-20 | 2023-09-27 | Amgen, Inc | Process for preparing 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3- yl)pyridof[2,3-d]pyrimidine-2,4(1h,3h)-dione |
| CN116390915A (zh) * | 2020-11-24 | 2023-07-04 | 杭州多域生物技术有限公司 | 一种芳香化合物、其制备方法及应用 |
| TW202227438A (zh) * | 2020-11-24 | 2022-07-16 | 大陸商杭州多域生物技術有限公司 | 一種芳香化合物、其製備方法及應用 |
| CN116490188A (zh) * | 2020-11-26 | 2023-07-25 | 上海翰森生物医药科技有限公司 | 含氮杂环类衍生物的盐、晶型及其制备方法和应用 |
| WO2022121839A1 (zh) * | 2020-12-08 | 2022-06-16 | 上海和誉生物医药科技有限公司 | 吡啶并[2,3-d]嘧啶-2(1H)-酮衍生物及其制备方法和应用 |
| WO2022125971A1 (en) * | 2020-12-11 | 2022-06-16 | Erasca, Inc. | Combination therapies for the treatment of cancer |
| CN114644628A (zh) * | 2020-12-17 | 2022-06-21 | 广东东阳光药业有限公司 | 嘧啶酮衍生物及其在药物中的应用 |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| TWI795129B (zh) * | 2020-12-18 | 2023-03-01 | 大陸商正大天晴藥業集團股份有限公司 | 吡啶并嘧啶酮類化合物 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CN114685502A (zh) * | 2020-12-25 | 2022-07-01 | 由理生物医药（上海）有限公司 | 作为kras-g12c抑制剂的螺环类化合物 |
| US20240091230A1 (en) | 2021-01-08 | 2024-03-21 | Amgen Inc. | Use of kras g12c inhibitor in treating cancers |
| EP4281457A4 (en) * | 2021-03-10 | 2024-07-31 | Beta Pharma, Inc. | PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS |
| US20240189313A1 (en) * | 2021-03-11 | 2024-06-13 | InventisBio Co., Ltd. | Solid dispersions |
| CN113018415B (zh) * | 2021-03-17 | 2022-07-01 | 遵义医科大学 | 一种药物组合及其应用 |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| JP2024514127A (ja) | 2021-04-09 | 2024-03-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗がん剤療法 |
| WO2022232318A1 (en) * | 2021-04-27 | 2022-11-03 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| AU2022265682A1 (en) | 2021-04-29 | 2023-11-09 | Amgen Inc. | 2-aminobenzothiazole compounds and methods of use thereof |
| CA3217393A1 (en) | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
| CN118852330A (zh) | 2021-05-05 | 2024-10-29 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| WO2022246459A1 (en) * | 2021-05-19 | 2022-11-24 | Genentech, Inc. | Combination therapy |
| WO2022246069A1 (en) | 2021-05-19 | 2022-11-24 | Teva Pharmaceuticals International Gmbh | Process for preparation of sotorasib and solid state form thereof |
| WO2022251296A1 (en) * | 2021-05-25 | 2022-12-01 | Erasca, Inc. | Sulfur-containing heteroaromatic tricyclic kras inhibitors |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| AR126166A1 (es) * | 2021-06-18 | 2023-09-27 | Antengene Discovery Ltd | Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| US20240287066A1 (en) | 2021-06-24 | 2024-08-29 | Sandoz Ag | Crystalline Form of Sotorasib |
| EP4227305A1 (en) | 2022-02-10 | 2023-08-16 | Sandoz AG | Crystalline form of sotorasib |
| US12441727B2 (en) | 2021-07-07 | 2025-10-14 | Incyte Corporation | Tricyclic compounds as inhibitors of KRAS |
| AU2022325858A1 (en) * | 2021-08-10 | 2024-02-15 | Amgen Inc. | Heterocyclic compounds and methods of use |
| CA3229855A1 (en) | 2021-08-31 | 2023-03-09 | Incyte Corporation | Naphthyridine compounds as inhibitors of kras |
| EP4395769A1 (en) | 2021-09-01 | 2024-07-10 | Novartis AG | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| EP4389751A1 (en) | 2021-09-03 | 2024-06-26 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| CN114605406B (zh) * | 2021-09-18 | 2023-05-26 | 都创(上海)医药开发有限公司 | Amg510化合物的晶型及其制备方法和用途 |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| PE20241129A1 (es) | 2021-10-01 | 2024-05-24 | Xinthera Inc | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos |
| WO2023056421A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| KR20240101561A (ko) | 2021-10-14 | 2024-07-02 | 인사이트 코포레이션 | Kras의 저해제로서의 퀴놀린 화합물 |
| KR20240089594A (ko) | 2021-10-22 | 2024-06-20 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 질소 함유 테트라시클릭 화합물, 이의 제조 방법 및 이의 의학적 응용 |
| AU2022380979A1 (en) | 2021-11-02 | 2024-06-06 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
| WO2023078424A1 (zh) * | 2021-11-05 | 2023-05-11 | 苏州信诺维医药科技股份有限公司 | Kras突变体抑制剂的晶型、其制备方法及其应用 |
| JP2024541508A (ja) | 2021-11-24 | 2024-11-08 | ジェネンテック， インコーポレイテッド | 治療用インダゾール化合物およびがんの治療における使用方法 |
| JP2024543912A (ja) | 2021-11-24 | 2024-11-26 | ジェネンテック， インコーポレイテッド | 二環式治療用化合物及びがんの処置における使用方法 |
| KR20240128852A (ko) | 2021-12-01 | 2024-08-27 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료를 위한 고리형 2-아미노-3-시아노 티오펜 및 유도체 |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| CN118339153A (zh) | 2021-12-22 | 2024-07-12 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的杂芳族化合物 |
| EP4452416A1 (en) | 2021-12-22 | 2024-10-30 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
| CN118804916B (zh) | 2022-01-21 | 2025-04-01 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN118974055A (zh) | 2022-02-16 | 2024-11-15 | 美国安进公司 | 作为突变kras蛋白抑制剂的喹唑啉化合物及其用途 |
| EP4479398A1 (en) | 2022-02-16 | 2024-12-25 | Amgen Inc. | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins |
| MX2024010828A (es) | 2022-03-07 | 2024-09-17 | Amgen Inc | Procedimiento para preparar 4-metil-2-propan-2-il-piridin-3-carbon itrilo. |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| KR20240163107A (ko) | 2022-03-11 | 2024-11-18 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| KR20240167633A (ko) | 2022-03-31 | 2024-11-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 종양 치료용 약학 조성물 |
| WO2023194310A1 (en) | 2022-04-04 | 2023-10-12 | Sanofi | Therapeutic combination of kras g12c inhibitor and tead inhibitor |
| WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
| IL316278A (en) | 2022-04-28 | 2024-12-01 | Xinthera Inc | TRICYCLIC PARP1 INHIBITORS AND THEIR USES |
| JPWO2023214576A1 (enExample) | 2022-05-06 | 2023-11-09 | ||
| AU2023285116A1 (en) | 2022-06-10 | 2024-12-19 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| KR20250060956A (ko) | 2022-08-05 | 2025-05-07 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| EP4573095A1 (en) | 2022-08-17 | 2025-06-25 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| GB202212641D0 (en) | 2022-08-31 | 2022-10-12 | Jazz Pharmaceuticals Ireland Ltd | Novel compounds |
| CN115368358A (zh) * | 2022-09-01 | 2022-11-22 | 浙江九洲药业股份有限公司 | 一种Sotorasib新晶型及其制备方法与应用 |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| KR20250116016A (ko) | 2022-11-09 | 2025-07-31 | 레볼루션 메디슨즈, 인크. | 화합물, 복합체 및 이들의 제조 및 사용 방법 |
| IL320913A (en) | 2022-11-21 | 2025-07-01 | Treeline Biosciences Inc | Spirocyclic dihydropyranopyrimidine KRAS inhibitors |
| WO2024159164A2 (en) | 2023-01-26 | 2024-08-02 | Arvinas Operations, Inc. | Cereblon-based kras degrading protacs ans uses related thereto |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN120813358A (zh) | 2023-04-06 | 2025-10-17 | 卫材R&D管理有限公司 | 用于治疗肿瘤的药物组合物 |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| TW202446388A (zh) | 2023-04-14 | 2024-12-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| CN120981456A (zh) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | 杂环化合物及其用途 |
| WO2024246114A1 (en) | 2023-05-31 | 2024-12-05 | Boehringer Ingelheim International Gmbh | Survivin as a biomarker for predicting the responsiveness of cancer treatment |
| WO2025007000A1 (en) | 2023-06-30 | 2025-01-02 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025034849A1 (en) * | 2023-08-08 | 2025-02-13 | Theras, Inc. | Fused pyridazines for the treatment of cancer and other indications |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| WO2025067459A2 (en) | 2023-09-29 | 2025-04-03 | D3 Bio (Wuxi) Co., Ltd. | Therapies for the treatment of cancer |
| WO2025076288A1 (en) | 2023-10-06 | 2025-04-10 | Amgen Inc. | Combination therapy for cancer treatment |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| US12466840B2 (en) | 2023-10-20 | 2025-11-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS proteins |
| WO2025119352A1 (zh) * | 2023-12-08 | 2025-06-12 | 中山优理生物医药有限公司 | 一种并环类mat2a抑制剂、包含其的药物组合物及其应用 |
| WO2025127968A2 (ru) * | 2023-12-14 | 2025-06-19 | Федеральное Государственное Бюджетное Учреждение "Российский Научный Центр Рентгенорадиологии" Министерства Здравоохранения Российской Федерации (Фгбу "Рнцрр" Минздрава России). | Ингибитор ras-гтфазы и его применение для лечения онкологических заболеваний |
| WO2025136346A1 (en) * | 2023-12-19 | 2025-06-26 | Amgen Inc. | Indazole containing compounds and methods of use |
| WO2025132549A1 (en) | 2023-12-20 | 2025-06-26 | Boehringer Ingelheim International Gmbh | Cancer combination therapy using zongertinib and a kras g12c inhibitor |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| WO2025171055A1 (en) | 2024-02-06 | 2025-08-14 | Kumquat Biosciences Inc. | Heterocyclic conjugates and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025194054A1 (en) | 2024-03-14 | 2025-09-18 | Amgen Inc. | Spirocyclic compounds as modulators of kras and uses thereof |
| WO2025194057A1 (en) | 2024-03-14 | 2025-09-18 | Amgen Inc. | Macrocyclic compounds as modulators of kras and uses thereof |
| WO2025217247A1 (en) | 2024-04-10 | 2025-10-16 | Amgen Inc. | Tethered spiro-heterocyclic inhibitors of kras g12c mutant proteins and uses thereof |
| WO2025230878A1 (en) | 2024-04-29 | 2025-11-06 | Amgen Inc. | Macrocyclic compounds as modulators of kras and uses thereof |
| WO2025230862A1 (en) | 2024-04-29 | 2025-11-06 | Amgen Inc. | Macrocyclic amino compounds as modulators of kras and uses therof |
| WO2025230971A1 (en) | 2024-04-30 | 2025-11-06 | Kumquat Biosciences Inc. | Macrocyclic heterocycles as anticancer agents |
| WO2025240582A1 (en) | 2024-05-14 | 2025-11-20 | Amgen Inc. | Macrocyclic compounds as modulators of kras and uses thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| CN118745175A (zh) * | 2024-06-07 | 2024-10-08 | 南昌大学 | 一种氘代索托拉西布及其制备方法与应用 |
Family Cites Families (235)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4232027A (en) | 1979-01-29 | 1980-11-04 | E. R. Squibb & Sons, Inc. | 1,2-Dihydro-2-oxo-4-phenyl-3-quinolinecarbonitrile derivatives |
| EP0090505B1 (en) | 1982-03-03 | 1990-08-08 | Genentech, Inc. | Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| JP2762522B2 (ja) | 1989-03-06 | 1998-06-04 | 藤沢薬品工業株式会社 | 血管新生阻害剤 |
| GB8912336D0 (en) | 1989-05-30 | 1989-07-12 | Smithkline Beckman Intercredit | Compounds |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| US5892112A (en) | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| CA2066898A1 (en) | 1991-04-29 | 1992-10-30 | Chuan Shih | Pharmaceutical compounds |
| WO1992020642A1 (en) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| AU669960B2 (en) | 1992-11-13 | 1996-06-27 | Immunex Corporation | Novel cytokine designated elk ligand |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5516658A (en) | 1993-08-20 | 1996-05-14 | Immunex Corporation | DNA encoding cytokines that bind the cell surface receptor hek |
| WO1995009847A1 (en) | 1993-10-01 | 1995-04-13 | Ciba-Geigy Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
| US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| JP4105761B2 (ja) | 1993-11-19 | 2008-06-25 | アボット・ラボラトリーズ | ラパミシン（マクロライド）の半合成類似体免疫調節剤 |
| JP3745772B2 (ja) | 1993-12-17 | 2006-02-15 | ノバルティス アクチエンゲゼルシャフト | 免疫抑制剤として有用なラパマイシン誘導体 |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| AU2096895A (en) | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| JPH09512167A (ja) | 1994-04-15 | 1997-12-09 | アムジエン・インコーポレーテツド | Ｈｅｋ５、ｈｅｋ７、ｈｅｋ８、ｈｅｋ１１、新規なｅｐｈ様受容体タンパク質チロシンキナーゼ |
| ATE159257T1 (de) | 1994-05-03 | 1997-11-15 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer wirkung |
| US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
| US5919905A (en) | 1994-10-05 | 1999-07-06 | Immunex Corporation | Cytokine designated LERK-6 |
| US6057124A (en) | 1995-01-27 | 2000-05-02 | Amgen Inc. | Nucleic acids encoding ligands for HEK4 receptors |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| EP0817775B1 (en) | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Quinazoline derivatives |
| NZ304859A (en) | 1995-04-03 | 2000-01-28 | Novartis Ag | 4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives, medicaments and processes for the preparation thereof |
| FI973974A7 (fi) | 1995-04-20 | 1997-10-16 | Pfizer | Aryylisulfonyylihydroksaamihappojohdannaisia MMP- ja TNF-inhibiittorei na |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| JP3226545B2 (ja) | 1995-06-09 | 2001-11-05 | ノバルティス・アクチエンゲゼルシャフト | ラパマイシン誘導体 |
| ATE212993T1 (de) | 1995-07-06 | 2002-02-15 | Novartis Erfind Verwalt Gmbh | Pyrolopyrimidine und verfahren zu ihrer herstellung |
| DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| DE69624081T2 (de) | 1995-12-20 | 2003-06-12 | Agouron Pharmaceuticals, Inc. | Matrix-metalloprotease Inhibitoren |
| ATE217873T1 (de) | 1996-01-23 | 2002-06-15 | Novartis Erfind Verwalt Gmbh | Pyrrolopyrimidinen und verfahren zu deren herstellung |
| JP3406763B2 (ja) | 1996-01-30 | 2003-05-12 | 東レ・ダウコーニング・シリコーン株式会社 | シリコーンゴム組成物 |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE19629652A1 (de) | 1996-03-06 | 1998-01-29 | Thomae Gmbh Dr K | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| BR9709443B1 (pt) | 1996-03-15 | 2009-05-05 | n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas. | |
| EP0892789B2 (en) | 1996-04-12 | 2009-11-18 | Warner-Lambert Company LLC | Irreversible inhibitors of tyrosine kinases |
| GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| DE69734513T2 (de) | 1996-06-24 | 2006-07-27 | Pfizer Inc. | Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten |
| WO1998002441A2 (en) | 1996-07-12 | 1998-01-22 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
| EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| CA2260058A1 (en) | 1996-07-13 | 1998-01-22 | Kathryn Jane Smith | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| HUP9903014A3 (en) | 1996-07-18 | 2000-08-28 | Pfizer | Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| JP4440344B2 (ja) | 1996-08-16 | 2010-03-24 | シェーリング コーポレイション | 哺乳動物細胞表面抗原；関連試薬 |
| IL128189A0 (en) | 1996-08-23 | 1999-11-30 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
| AU720429B2 (en) | 1996-08-23 | 2000-06-01 | Novartis Ag | Substituted pyrrolopyrimidines and processes for their preparation |
| EP0929553B1 (en) | 1996-10-02 | 2005-03-16 | Novartis AG | Pyrimidine derivatives and processes for the preparation thereof |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| WO1998014449A1 (en) | 1996-10-02 | 1998-04-09 | Novartis Ag | Fused pyrazole derivatives and processes for their preparation |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
| ES2224277T3 (es) | 1997-01-06 | 2005-03-01 | Pfizer Inc. | Derivados de sulfonas ciclicas. |
| PT977733E (pt) | 1997-02-03 | 2003-12-31 | Pfizer Prod Inc | Derivados de acido arilsulfonilamino-hidroxamico |
| DE69839338T2 (de) | 1997-02-05 | 2008-07-10 | Warner-Lambert Company Llc | Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| IL131123A0 (en) | 1997-02-11 | 2001-01-28 | Pfizer | Arylsulfonyl hydroxamic acid derivatives |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US6150395A (en) | 1997-05-30 | 2000-11-21 | The Regents Of The University Of California | Indole-3-carbinol (I3C) derivatives and methods |
| US6329375B1 (en) | 1997-08-05 | 2001-12-11 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
| ES2216293T3 (es) | 1997-08-08 | 2004-10-16 | Pfizer Products Inc. | Derivados de acido ariloxiarilsulfonilamino-hidroxamico. |
| WO2000012089A1 (en) | 1998-08-31 | 2000-03-09 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| CA2308114A1 (en) | 1997-10-21 | 1999-04-29 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| JP2002502607A (ja) | 1998-02-09 | 2002-01-29 | ジェネンテク・インコーポレイテッド | 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸 |
| CA2322311C (en) | 1998-03-04 | 2009-10-13 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| TR200003514T2 (tr) | 1998-05-29 | 2002-05-21 | Sugen Inc. | Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| JP2002520324A (ja) | 1998-07-10 | 2002-07-09 | メルク エンド カムパニー インコーポレーテッド | 新規な血管形成インヒビター |
| DK1004578T3 (da) | 1998-11-05 | 2004-06-28 | Pfizer Prod Inc | 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater |
| ES2384160T3 (es) | 1999-01-13 | 2012-07-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
| PT1165085E (pt) | 1999-03-30 | 2006-10-31 | Novartis Ag | Derivados de ftalazina para tratar doencas inflamatorias |
| GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
| US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
| IL146482A0 (en) | 1999-06-07 | 2002-07-25 | Immunex Corp | Tek antagonists |
| DK1196186T3 (da) | 1999-07-12 | 2008-03-03 | Genentech Inc | Stimulering eller inhibering af angiogenese og kardiovaskularisation med tumornekrosefaktorligand/receptorhomologer |
| EP1212331B1 (en) | 1999-08-24 | 2004-04-21 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| EP1676845B1 (en) | 1999-11-05 | 2008-06-11 | AstraZeneca AB | New quinazoline derivatives |
| PT1233943E (pt) | 1999-11-24 | 2011-09-01 | Sugen Inc | Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres |
| US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
| IL151032A0 (en) | 2000-02-25 | 2003-04-10 | Immunex Corp | Integrin antagonists |
| EE05450B1 (et) | 2000-07-19 | 2011-08-15 | Warner-Lambert Company | 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine |
| US6630500B2 (en) | 2000-08-25 | 2003-10-07 | Cephalon, Inc. | Selected fused pyrrolocarbazoles |
| KR100847169B1 (ko) | 2000-12-21 | 2008-07-17 | 글락소 그룹 리미티드 | 혈관형성 조절제로서의 피리미딘아민 |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US20050026868A1 (en) | 2003-07-11 | 2005-02-03 | Metcalf Chester A. | Phosphorus-containing macrocycles |
| JP2002233610A (ja) | 2002-02-18 | 2002-08-20 | Olympia:Kk | スロットマシン |
| US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| US20050009849A1 (en) | 2003-01-03 | 2005-01-13 | Veach Darren R. | Pyridopyrimidine kinase inhibitors |
| MXPA05012475A (es) | 2003-05-23 | 2006-05-25 | Wyeth Corp | Anticuerpos y moleculas relacionadas con el ligando para el receptor tnf inducido por glucorticoides (gitr) y el ligando (gitr) y usos de los mismos. |
| MXPA06000117A (es) | 2003-07-08 | 2006-04-27 | Novartis Ag | Uso de rapamicina y derivados de rapamicina para el tratamiento de perdida osea. |
| WO2005007190A1 (en) | 2003-07-11 | 2005-01-27 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
| TW200523262A (en) | 2003-07-29 | 2005-07-16 | Smithkline Beecham Corp | Inhibitors of AKT activity |
| AU2004268941A1 (en) | 2003-08-22 | 2005-03-10 | Avanir Pharmaceuticals | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
| EP1692318A4 (en) | 2003-12-02 | 2008-04-02 | Genzyme Corp | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| WO2006083289A2 (en) | 2004-06-04 | 2006-08-10 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| MX2007002312A (es) | 2004-08-26 | 2007-04-16 | Pfizer | Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa. |
| TW200626610A (en) | 2004-10-13 | 2006-08-01 | Wyeth Corp | Analogs of 17-hydroxywortmannin as PI3K inhibitors |
| MX2007004551A (es) | 2004-10-18 | 2007-05-23 | Amgen Inc | Compuestos tiadiazol y metodos de uso. |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| JP4361545B2 (ja) | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| BRPI0616202A2 (pt) | 2005-09-20 | 2011-06-14 | Pfizer Prod Inc | formas de dosagem e uso de um inibidor da tirosina quinase |
| EP1981884B1 (en) | 2006-01-18 | 2012-06-13 | Amgen, Inc | Thiazole compounds as protein kinase b (pkb) inhibitors |
| EP1981969A4 (en) | 2006-01-19 | 2009-06-03 | Genzyme Corp | ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER |
| AU2007329352B2 (en) | 2006-12-07 | 2013-01-17 | F. Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| PL2137186T3 (pl) | 2007-03-23 | 2016-09-30 | Związki heterocykliczne i ich zastosowania | |
| AU2008231384B2 (en) | 2007-03-23 | 2011-09-15 | Amgen Inc. | Heterocyclic compounds and their use |
| US7705018B2 (en) | 2007-03-23 | 2010-04-27 | Amgen Inc. | Substituted quinolines and their uses in treatment of inflammatory and related conditions |
| WO2008153947A2 (en) | 2007-06-07 | 2008-12-18 | Amgen Inc. | Heterocyclic compounds as raf kinase modulators |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| AU2008276521B2 (en) | 2007-07-17 | 2011-11-03 | Amgen Inc. | Heterocyclic modulators of PKB |
| AU2008276512A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of PKB |
| ES2401557T3 (es) | 2007-08-02 | 2013-04-22 | Amgen, Inc | Moduladores de Pl3 cinasas y métodos de uso |
| EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| US7820665B2 (en) | 2007-12-19 | 2010-10-26 | Amgen Inc. | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment |
| CA2709202C (en) | 2007-12-19 | 2013-04-23 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| WO2009126584A1 (en) | 2008-04-07 | 2009-10-15 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
| WO2009155121A2 (en) | 2008-05-30 | 2009-12-23 | Amgen Inc. | Inhibitors of pi3 kinase |
| MX2011000039A (es) | 2008-07-02 | 2011-05-31 | Emergent Product Dev Seattle | Proteinas antagonistas del factor-beta de crecimiento transformante (tgf-beta), que se unen a multiples objetivos. |
| CN102149820B (zh) | 2008-09-12 | 2014-07-23 | 国立大学法人三重大学 | 能够表达外源gitr配体的细胞 |
| US20110263647A1 (en) | 2009-01-15 | 2011-10-27 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
| CA2752527C (en) | 2009-02-18 | 2014-09-23 | Amgen Inc. | Indole/benzimidazole compounds as mtor kinase inhibitors |
| MX2011009796A (es) | 2009-03-20 | 2011-12-14 | Amgen Inc | Inhibidores de la cinasa pi3. |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| JP2012526836A (ja) | 2009-05-13 | 2012-11-01 | アムジエン・インコーポレーテツド | Ｐｉｋｋ阻害薬としてのヘテロアリール化合物 |
| US8754089B2 (en) | 2009-06-25 | 2014-06-17 | Amgen Inc. | Heterocyclic compounds and their uses |
| CA2765819A1 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses as inhibitors of pi3 k activity |
| WO2010151791A1 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses |
| SG176986A1 (en) | 2009-06-25 | 2012-02-28 | Amgen Inc | Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases |
| EP2266984A1 (en) * | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis |
| CN103951753B (zh) | 2009-09-03 | 2018-01-12 | 默沙东公司 | 抗‑gitr抗体 |
| EP2818170B1 (en) | 2009-09-11 | 2018-12-05 | Amgen, Inc | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
| GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
| WO2011075747A1 (en) * | 2009-12-18 | 2011-06-23 | Glaxosmithkline Llc | Therapeutic compounds |
| WO2011090762A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Heterodimer binding proteins and uses thereof |
| EP2696682B1 (en) | 2011-04-13 | 2018-03-21 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
| US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| EP2882746B1 (en) | 2012-08-07 | 2016-12-07 | Merck Patent GmbH | Pyridopyrimidine derivatives as protein kinase inhibitors |
| TW201524952A (zh) | 2013-03-15 | 2015-07-01 | Araxes Pharma Llc | Ｋｒａｓ ｇ１２ｃ之共價抑制劑 |
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
| GB201312059D0 (en) | 2013-07-05 | 2013-08-21 | Univ Leuven Kath | Novel GAK modulators |
| CN106488910B (zh) * | 2013-10-10 | 2020-07-31 | 亚瑞克西斯制药公司 | Kras g12c的抑制剂 |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2015109285A1 (en) | 2014-01-20 | 2015-07-23 | Cleave Biosciences, Inc. | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX |
| WO2016035008A1 (en) | 2014-09-04 | 2016-03-10 | Lupin Limited | Pyridopyrimidine derivatives as mek inhibitors |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| EP3197870B1 (en) | 2014-09-25 | 2020-08-19 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| CA2981677A1 (en) | 2015-04-03 | 2016-10-06 | Nantbioscience, Inc. | Compositions and methods of targeting mutant k-ras |
| EP3280708B1 (en) | 2015-04-10 | 2021-09-01 | Araxes Pharma LLC | Substituted quinazoline compounds and methods of use thereof |
| JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法 |
| CA2993013A1 (en) | 2015-07-22 | 2017-01-26 | Araxes Pharma Llc | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EA038635B9 (ru) | 2015-11-16 | 2021-10-26 | Араксис Фарма Ллк | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения |
| WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| EP3458445B1 (en) * | 2016-05-18 | 2021-02-17 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| EP3519402A1 (en) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| MY196830A (en) | 2016-12-22 | 2023-05-03 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| US20200385364A1 (en) | 2017-01-26 | 2020-12-10 | Araxes Pharma Llc | Fused n-heterocyclic compounds and methods of use thereof |
| JOP20190272A1 (ar) * | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| CN110831933A (zh) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | 喹唑啉衍生物作为突变kras、hras或nras的调节剂 |
| AR112797A1 (es) | 2017-09-08 | 2019-12-11 | Amgen Inc | Inhibidores de kras g12c y métodos para utilizarlos |
| AU2019262599B2 (en) | 2018-05-04 | 2023-10-12 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| WO2019213516A1 (en) * | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| ES2986917T3 (es) | 2018-05-10 | 2024-11-13 | Amgen Inc | Inhibidores de KRAS G12C para el tratamiento del cáncer |
| CA3098885A1 (en) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| US20190375749A1 (en) | 2018-06-11 | 2019-12-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| JP7369719B2 (ja) | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法 |
| WO2019243533A1 (en) | 2018-06-21 | 2019-12-26 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| MA52942A (fr) | 2018-06-21 | 2021-04-28 | Janssen Pharmaceutica Nv | Composés inhibiteurs d'oga |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| US11053226B2 (en) | 2018-11-19 | 2021-07-06 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| CA3225293A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
| US12252486B2 (en) | 2019-05-21 | 2025-03-18 | Amgen Inc. | Solid state forms |
| EP4048671A1 (en) | 2019-10-24 | 2022-08-31 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| EP4058453A1 (en) | 2019-11-14 | 2022-09-21 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| US12473281B2 (en) | 2019-11-14 | 2025-11-18 | Amgen Inc. | Synthesis of KRAS G12C inhibitor compound |
| US20230028414A1 (en) | 2019-12-16 | 2023-01-26 | Amgen Inc. | Dosing regimen of kras g12c inhibitor |
-
2017
- 2017-06-16 JO JOP/2019/0272A patent/JOP20190272A1/ar unknown
-
2018
- 2018-05-21 SM SM20220053T patent/SMT202200053T1/it unknown
- 2018-05-21 PE PE2019002456A patent/PE20200733A1/es unknown
- 2018-05-21 LT LTEPPCT/US2018/033714T patent/LT3630761T/lt unknown
- 2018-05-21 KR KR1020197037502A patent/KR102300499B1/ko active Active
- 2018-05-21 SI SI201830527T patent/SI3630761T1/sl unknown
- 2018-05-21 CN CN202211265391.0A patent/CN115626923B/zh active Active
- 2018-05-21 UA UAA201912099A patent/UA127968C2/uk unknown
- 2018-05-21 CR CR20240126A patent/CR20240126A/es unknown
- 2018-05-21 EA EA201992781A patent/EA201992781A1/ru unknown
- 2018-05-21 HR HRP20212017TT patent/HRP20212017T1/hr unknown
- 2018-05-21 EP EP21201361.9A patent/EP3974429A1/en active Pending
- 2018-05-21 PT PT187316245T patent/PT3630761T/pt unknown
- 2018-05-21 US US15/984,855 patent/US10519146B2/en active Active
- 2018-05-21 BR BR112019024525-1A patent/BR112019024525B1/pt active IP Right Grant
- 2018-05-21 DK DK18731624.5T patent/DK3630761T3/da active
- 2018-05-21 MX MX2019013858A patent/MX386189B/es unknown
- 2018-05-21 ES ES18731624T patent/ES2905676T3/es active Active
- 2018-05-21 AU AU2018273356A patent/AU2018273356B2/en active Active
- 2018-05-21 CA CA3063469A patent/CA3063469C/en active Active
- 2018-05-21 CR CR20190534A patent/CR20190534A/es unknown
- 2018-05-21 CN CN201880047910.1A patent/CN110997668B/zh active Active
- 2018-05-21 TW TW111135162A patent/TWI834294B/zh active
- 2018-05-21 MY MYPI2019006806A patent/MY199303A/en unknown
- 2018-05-21 KR KR1020217028358A patent/KR102573230B1/ko active Active
- 2018-05-21 RS RS20220019A patent/RS62800B1/sr unknown
- 2018-05-21 NZ NZ758786A patent/NZ758786A/en unknown
- 2018-05-21 KR KR1020247025384A patent/KR20240119348A/ko active Pending
- 2018-05-21 WO PCT/US2018/033714 patent/WO2018217651A1/en not_active Ceased
- 2018-05-21 TW TW107117297A patent/TWI780154B/zh active
- 2018-05-21 HU HUE18731624A patent/HUE057632T2/hu unknown
- 2018-05-21 PL PL18731624T patent/PL3630761T3/pl unknown
- 2018-05-21 SG SG10201913195RA patent/SG10201913195RA/en unknown
- 2018-05-21 EP EP18731624.5A patent/EP3630761B1/en active Active
- 2018-05-21 MA MA48772A patent/MA48772B1/fr unknown
- 2018-05-21 KR KR1020237029215A patent/KR102690360B1/ko active Active
- 2018-05-22 AR ARP180101353A patent/AR111882A1/es active IP Right Grant
- 2018-05-22 JP JP2018097648A patent/JP6785819B2/ja active Active
- 2018-05-22 UY UY0001037744A patent/UY37744A/es active IP Right Grant
-
2019
- 2019-10-23 US US16/661,907 patent/US20200055845A1/en not_active Abandoned
- 2019-11-07 IL IL270490A patent/IL270490B/en unknown
- 2019-11-18 PH PH12019502579A patent/PH12019502579A1/en unknown
- 2019-11-19 ZA ZA2019/07651A patent/ZA201907651B/en unknown
- 2019-11-20 MX MX2021011115A patent/MX2021011115A/es unknown
- 2019-11-20 CO CONC2019/0013010A patent/CO2019013010A2/es unknown
- 2019-11-21 CL CL2019003394A patent/CL2019003394A1/es unknown
- 2019-11-24 SA SA522432081A patent/SA522432081B1/ar unknown
- 2019-11-24 SA SA519410622A patent/SA519410622B1/ar unknown
-
2020
- 2020-09-17 CL CL2020002405A patent/CL2020002405A1/es unknown
- 2020-09-24 US US17/031,607 patent/US11905281B2/en active Active
- 2020-10-27 JP JP2020179494A patent/JP7095052B2/ja active Active
-
2021
- 2021-01-29 ZA ZA2021/00644A patent/ZA202100644B/en unknown
- 2021-06-28 AR ARP210101802A patent/AR122786A2/es active IP Right Grant
- 2021-06-28 AR ARP210101805A patent/AR122789A2/es active IP Right Grant
- 2021-06-28 AR ARP210101800A patent/AR122784A2/es unknown
- 2021-06-28 AR ARP210101799A patent/AR122783A2/es unknown
- 2021-06-28 AR ARP210101801A patent/AR122785A2/es active IP Right Grant
- 2021-06-28 AR ARP210101804A patent/AR122788A2/es active IP Right Grant
- 2021-06-28 AR ARP210101806A patent/AR122790A2/es active IP Right Grant
- 2021-06-28 AR ARP210101803A patent/AR122787A2/es active IP Right Grant
- 2021-10-06 AU AU2021245150A patent/AU2021245150C1/en active Active
-
2022
- 2022-01-27 CY CY20221100074T patent/CY1125289T1/el unknown
- 2022-02-07 IL IL290399A patent/IL290399B2/en unknown
- 2022-03-02 ZA ZA2022/02559A patent/ZA202202559B/en unknown
- 2022-06-21 JP JP2022099389A patent/JP7495444B2/ja active Active
-
2023
- 2023-11-09 AU AU2023263502A patent/AU2023263502A1/en not_active Abandoned
- 2023-12-18 US US18/543,498 patent/US20240174660A1/en active Pending
-
2024
- 2024-05-22 JP JP2024083128A patent/JP7717224B2/ja active Active
-
2025
- 2025-08-26 AU AU2025223741A patent/AU2025223741A1/en active Pending